AP1 Reporter BioAssay™ Kit (JNK Pathway)

Cat# 171824-500T

Size : 500Tests

Brand : US Biological

Request more information



171824 AP1 Reporter BioAssay™ Kit (JNK Pathway)

Clone Type
Polyclonal
Shipping Temp
Blue Ice
Storage Temp
-20°C/-70°C

The AP1 Reporter BioAssay™ Kit is designed for monitoring the activity of the JNK signaling pathway and the transcriptional activity of AP1 in cultured cells. The kit contains a transfection-ready AP1 luciferase reporter vector. This reporter contains the firefly luciferase gene under the control of multimerized AP1 responsive elements located upstream of a minimal promoter. The AP1 reporter is premixed with a constitutively expressing Renilla luciferase vector that serves as an internal control for transfection efficiency. The kit also includes a non-inducible firefly luciferase vector premixed with constitutively expressing Renilla luciferase vector as a negative control. The non-inducible luciferase vector contains the firefly luciferase gene under the control of a minimal promoter, without any additional response elements. The negative control is critical for determining pathway-specific effects and the background luciferase activity.||Applications:|Monitor JNK signaling pathway activity and AP1-mediated activity.|Screen for activators or inhibitors of the JNK signaling pathway.|Study effects of RNAi or gene overexpression on the activity of the JNK pathway.||Components:|Reporter (Component A), AP1 luciferase reporter vector + constitutively expressing Renilla luciferase vector, 1x500ul (60ng DNA/ul)|Negative Control Reporter (Component B), Non-inducble luciferase vector + constitutively expressing Renilla luciferase vector, 1x500ul (60ng DNA/ul)||Storage and Stability:|Store powder at 4°C liquid at -20°C. Store other components at 4°C. Stable for at least 6 months For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Applications
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
References
1. Zhou H. et. al. (2005) Frequency and distribution of AP-1 sites in the human genome. DNA Research. 11: 139-150. 2. Gaillard P. et.al. (2005) Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. J Med Chem. 48(14):4596-4607.